
ALT Peptigrity tier list, part 1 of 3: fat loss. Peptides ranked by how far each one got in human trials. S tier, approved for this use in the US or EU: semaglutide, tirzepatide. A tier, phase 3 done but no US or EU approval: retatrutide, CagriSema, survodutide, mazdutide, cagrilintide, tesamorelin. B tier, small or early human trials: eloralintide. C tier, animal or cell data only: MOTS-c, adipotide. D tier, almost nothing published: HGH Frag 176-191. F tier, tested in humans and flopped: AOD-9604. Not a peptide: orforglipron, 5-Amino-1MQ, SLU-PP-332. Each compound has a one-line summary of its human evidence and its count of lab tests on file at Peptigrity. A sticker says only 2 peptides in the whole series made S tier.

ALT Peptigrity tier list, part 3 of 3: healing and repair. S tier and A tier are empty. B tier, small or early human trials: GHK-Cu, ARA-290, and collagen peptides, marked for scale. C tier, animal or cell data only: BPC-157, TB-500, KPV, each tagged as named in HHS's October 28, 2026 compounding policy. D tier, almost nothing published: pentadeca arginate, BPC plus TB blends. F tier, tested in humans and flopped: LL-37. A box at the bottom compares 951 lab tests of BPC-157 vials on file at Peptigrity with 1 human study in a 2025 review of its sports-injury research.















